These findings suggest that treatment with the selective htr2b antagonist enhances hyperinsulinemia and suppresses hyperglycemia and the decreases in plasma FGF21 levels and hepatic FGF21, Sdf2l1, and htr2a expression in db/db mice. Here, HTR2B is linked to Hyperinsulinemia.